About
Overview
Leadership
Pipeline
Overview
ONCT-808
ONCT-534
Zilovertamab
Science
Overview
Publications
Investors
Overview
News Releases
Events & Presentations
Financial Reports
Stock Information
Analyst Coverage
Corporate Governance
Patients
Careers
Current Opportunities
Vision, Mission and Impact
Contact
M. Wang 2024 EHA Poster: A Multi-Center, Open-Label, Phase 1/2 Study of ONCT-808, A ROR1-Targeting CAR T Cell Therapy, in Adults with Relapsed/Refractory Aggressive B Cell Lymphomas
Please ensure Javascript is enabled for purposes of
website accessibility
About
Overview
Leadership
Pipeline
Overview
ONCT-808
ONCT-534
Zilovertamab
Science
Overview
Publications
Investors
Overview
News Releases
Events & Presentations
Financial Reports
Stock Information
Analyst Coverage
Corporate Governance
Patients
Careers
Current Opportunities
Vision, Mission and Impact
Contact